BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 24675571)

  • 1. Sex differences in overall and cause-specific mortality among HIV-infected adults on antiretroviral therapy in Europe, Canada and the US.
    Antiretroviral Therapy Cohort Collaboration (ART-CC)
    Antivir Ther; 2015; 20(1):21-8. PubMed ID: 24675571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics and determinants of T-cell phenotype normalization in HIV-1-infected individuals receiving long-term antiretroviral therapy.
    Ndumbi P; Gillis J; Raboud J; Cooper C; Hogg RS; Montaner JS; Burchell AN; Loutfy MR; Machouf N; Klein MB; Tsoukas C;
    HIV Med; 2014 Mar; 15(3):153-64. PubMed ID: 24304582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality in HIV-infected women, heterosexual men, and men who have sex with men in Rio de Janeiro, Brazil: an observational cohort study.
    Coelho L; Grinsztejn B; Castilho JL; De Boni R; Quintana MS; Campos DP; Ribeiro SR; Pacheco AG; Veloso VG; Luz PM
    Lancet HIV; 2016 Oct; 3(10):e490-8. PubMed ID: 27658875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of geographical origin and ethnicity on mortality in patients on antiretroviral therapy in Canada, Europe, and the United States.
    Antiretroviral Therapy Cohort Collaboration (ART-CC)
    Clin Infect Dis; 2013 Jun; 56(12):1800-9. PubMed ID: 23457077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC).
    Trickey A; May MT; Schommers P; Tate J; Ingle SM; Guest JL; Gill MJ; Zangerle R; Saag M; Reiss P; Monforte AD; Johnson M; Lima VD; Sterling TR; Cavassini M; Wittkop L; Costagliola D; Sterne JAC;
    Clin Infect Dis; 2017 Sep; 65(6):959-966. PubMed ID: 28903507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased risk of non-AIDS-related events in HIV subjects with persistent low CD4 counts despite cART in the CoRIS cohort.
    Pacheco YM; Jarrin I; Rosado I; Campins AA; Berenguer J; Iribarren JA; Rivero M; Muñoz-Medina L; Bernal-Morell E; Gutiérrez F; Leal M;
    Antiviral Res; 2015 May; 117():69-74. PubMed ID: 25766861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain.
    Rodríguez-Arenas MA; Jarrín I; del Amo J; Iribarren JA; Moreno S; Viciana P; Peña A; Sirvent JL; Vidal F; Lacruz J; Gutierrez F; Oteo JA; Asencio R; Castilla J; Hoyos SP;
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):715-23. PubMed ID: 16910826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes of first-line antiretroviral therapy in Latin America: analysis from the LATINA retrospective cohort study.
    Angriman F; Belloso WH; Sierra-Madero J; Sánchez J; Moreira RI; Kovalevski LO; Orellana LC; Cardoso SW; Crabtree-Ramirez B; La Rosa A; Losso MH
    Int J STD AIDS; 2016 Feb; 27(2):118-26. PubMed ID: 25740759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies.
    Antiretroviral Therapy Cohort Collaboration
    Clin Infect Dis; 2010 May; 50(10):1387-96. PubMed ID: 20380565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does gender or mode of HIV acquisition affect virological response to modern antiretroviral therapy (ART)?
    Saunders P; Goodman AL; Smith CJ; Marshall N; O'Connor JL; Lampe FC; Johnson MA
    HIV Med; 2016 Jan; 17(1):18-27. PubMed ID: 26140659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies.
    Antiretroviral Therapy Cohort Collaboration
    Lancet HIV; 2017 Aug; 4(8):e349-e356. PubMed ID: 28501495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 subtypes and response to combination antiretroviral therapy in Europe.
    Bannister WP; Ruiz L; Loveday C; Vella S; Zilmer K; Kjaer J; Knysz B; Phillips AN; Mocroft A;
    Antivir Ther; 2006; 11(6):707-15. PubMed ID: 17310815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV.
    Neuhaus J; Angus B; Kowalska JD; La Rosa A; Sampson J; Wentworth D; Mocroft A;
    AIDS; 2010 Mar; 24(5):697-706. PubMed ID: 20177360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.
    del Amo J; Moreno S; Bucher HC; Furrer H; Logan R; Sterne J; Pérez-Hoyos S; Jarrín I; Phillips A; Lodi S; van Sighem A; de Wolf W; Sabin C; Bansi L; Justice A; Goulet J; Miró JM; Ferrer E; Meyer L; Seng R; Toulomi G; Gargalianos P; Costagliola D; Abgrall S; Hernán MA;
    Clin Infect Dis; 2012 May; 54(9):1364-72. PubMed ID: 22460971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study.
    Cornell M; Schomaker M; Garone DB; Giddy J; Hoffmann CJ; Lessells R; Maskew M; Prozesky H; Wood R; Johnson LF; Egger M; Boulle A; Myer L;
    PLoS Med; 2012; 9(9):e1001304. PubMed ID: 22973181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of non-AIDS-defining events among HIV-infected patients not yet on antiretroviral therapy.
    Zhang S; van Sighem A; Kesselring A; Gras L; Prins JM; Hassink E; Kauffmann R; Richter C; de Wolf F; Reiss P;
    HIV Med; 2015 May; 16(5):265-72. PubMed ID: 25604160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.
    Lapadula G; Cozzi-Lepri A; Marchetti G; Antinori A; Chiodera A; Nicastri E; Parruti G; Galli M; Gori A; Monforte Ad;
    AIDS; 2013 Mar; 27(5):769-79. PubMed ID: 23719349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
    Panel de expertos de GESIDA y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.